Elsevier

Fertility and Sterility

Volume 104, Issue 2, August 2015, Pages 286-291
Fertility and Sterility

Original article
Whole-exome sequencing identifies novel homozygous mutation in NPAS2 in family with nonobstructive azoospermia

https://doi.org/10.1016/j.fertnstert.2015.04.001Get rights and content
Under an Elsevier user license
open archive

Objective

To investigate the genetic cause of nonobstructive azoospermia (NOA) in a consanguineous Turkish family through homozygosity mapping followed by targeted exon/whole-exome sequencing to identify genetic variations.

Design

Whole-exome sequencing (WES).

Setting

Research laboratory.

Patient(s)

Two siblings in a consanguineous family with NOA.

Intervention(s)

Validating all variants passing filter criteria with Sanger sequencing to confirm familial segregation and absence in the control population.

Main Outcome Measure(s)

Discovery of a mutation that could potentially cause NOA.

Result(s)

A novel nonsynonymous mutation in the neuronal PAS-2 domain (NPAS2) was identified in a consanguineous family from Turkey. This mutation in exon 14 (chr2: 101592000 C>G) of NPAS2 is likely a disease-causing mutation as it is predicted to be damaging, it is a novel variant, and it segregates with the disease. Family segregation of the variants showed the presence of the homozygous mutation in the three brothers with NOA and a heterozygous mutation in the mother as well as one brother and one sister who were both fertile. The mutation is not found in the single-nucleotide polymorphism database, the 1000 Genomes Project, the Baylor College of Medicine cohort of 500 Turkish patients (not a population-specific polymorphism), or the matching 50 fertile controls.

Conclusion(s)

With the use of WES we identified a novel homozygous mutation in NPAS2 as a likely disease-causing variant in a Turkish family diagnosed with NOA. Our data reinforce the clinical role of WES in the molecular diagnosis of highly heterogeneous genetic diseases for which conventional genetic approaches have previously failed to find a molecular diagnosis.

Key Words

Circadian rhythm
consanguineous
genome
male infertility
spermatogenesis

Cited by (0)

R.R. has nothing to disclose. M.E.B. has nothing to disclose. C.C. has nothing to disclose. E.K. has nothing to disclose. J.S. has nothing to disclose. S.N.J. has nothing to disclose. Z.C.A. has nothing to disclose. M.B. has nothing to disclose. Y.Y. has nothing to disclose. C.H. has nothing to disclose. R.A.G. is interim chief scientific officer of Baylor Medical Genetics Laboratory. J.R.L. has stock ownership in 23 and Me and Ion Torrent Systems, is a paid consultant for Regeneron, is on the board of directors for Lasergen, and is a coinventor on multiple U.S. and European patents related to molecular diagnostics. D.J.L. has nothing to disclose. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered in the Medical Genetics Laboratory (MGL; http://www.bcm.edu/geneticlabs/).

Supported by a K12 scholarship (to R.R.), a Male Reproductive Health Research (MRHR) Career Development Physician-Scientist Award (Grant HD073917–01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program (to D.J.L.), and in part by the National Institutes of Health National Human Genome Research Institute (Grants 5 U54 HG003273) (to R.A.G.) and (Grants RO1NS058529 and U54HG006542) (J.R.L.).